Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Takaiti

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeysY Yamada, M Endo, M Kohno, et al.
Arzneimittel-Forschung|March 1, 1989
Metabolic fate of the new anti-ulcer drug enprostil in animals. 4th communication: effect on hepatic drug metabolizing enzyme system in ratsY Yamada, M Nakahara, M Kohno, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1991
First pass metabolism and in vitro metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine in dogsM Yoshikawa, S Nishiyama, H Endo, et al.
Journal of Pharmacobio-Dynamics|September 1, 1991
Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1- methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogsY Ito, T Fukushima, Y Sugawara, et al.
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 1st communication: absorption, pharmacokinetics and excretion in rats and dogsY Yamada, M Endo, M Kohno, et al.
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 5th communication: isolation and identification of metabolites of imidapril in rats, dogs, and monkeysY Yamada, R Ohashi, Y Sugawara, et al.
Journal of Pharmacobio-Dynamics|April 1, 1990
Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogsM Yoshikawa, H Endo, K Komatsu, et al.
European Journal of Pharmacology|March 5, 1991
Binding characteristics of a new 1,5-benzothiazepine, clentiazem, to rat cerebral cortex and skeletal muscle membranesT Suzuki, H Kurosawa, K Naito, et al.
Biological & Pharmaceutical Bulletin|July 1, 1993
Disposition and metabolic fate of clentiazem in rats and dogsS Nakamura, Y Sugawara, T Fukushima, et al.
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 3rd communication: tissue accumulation after consecutive oral administration of [N-methyl-14C]-imidapril in ratsY Yamada, M Endo, M Kohno, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeysY Yamada, M Endo, M Kohno, et al.
Arzneimittel-Forschung|March 1, 1989
Metabolic fate of the new anti-ulcer drug enprostil in animals. 4th communication: effect on hepatic drug metabolizing enzyme system in ratsY Yamada, M Nakahara, M Kohno, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1991
First pass metabolism and in vitro metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine in dogsM Yoshikawa, S Nishiyama, H Endo, et al.
Journal of Pharmacobio-Dynamics|September 1, 1991
Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1- methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogsY Ito, T Fukushima, Y Sugawara, et al.
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 1st communication: absorption, pharmacokinetics and excretion in rats and dogsY Yamada, M Endo, M Kohno, et al.
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 5th communication: isolation and identification of metabolites of imidapril in rats, dogs, and monkeysY Yamada, R Ohashi, Y Sugawara, et al.
Journal of Pharmacobio-Dynamics|April 1, 1990
Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogsM Yoshikawa, H Endo, K Komatsu, et al.
European Journal of Pharmacology|March 5, 1991
Binding characteristics of a new 1,5-benzothiazepine, clentiazem, to rat cerebral cortex and skeletal muscle membranesT Suzuki, H Kurosawa, K Naito, et al.
Biological & Pharmaceutical Bulletin|July 1, 1993
Disposition and metabolic fate of clentiazem in rats and dogsS Nakamura, Y Sugawara, T Fukushima, et al.
Arzneimittel-Forschung|April 1, 1992
Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 3rd communication: tissue accumulation after consecutive oral administration of [N-methyl-14C]-imidapril in ratsY Yamada, M Endo, M Kohno, et al.
Pageof 3